Morning Market Movers: FGI, ARX, CLBT, HLIT See Big Swings

The article lists Thursday premarket movers, citing large early price swings in multiple stocks. Gainers include FGI Industries (FGI) up 91% to $9.24, Accelerant Holdings (ARX) up 45% to $19.67, and Harmonic (HLIT) up 23% to $14.74. Losers include Cellebrite DI (CLBT) down 28% to $11.01 and Securitize (SECZ) down 21% to $6.25.

Original reporting
Published Aug 13, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$FGI
Bullish
low confidence
Mentioned
$FGI · $ARX · $HLIT · $CLBT · $OMER · $LNSR
Relevance
4/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$FGIBullishLow
01

Why it matters

The only actionable information is the magnitude of premarket gaps; the article does not provide any underlying fundamental or event driver, limiting conviction for follow-through trades.

02

Market read

A high-dispersion premarket tape suggests elevated volatility opportunities, but the lack of catalysts makes it more of a trading-flow snapshot than a news-driven setup.

03

What to watch

Premarket % moves can be driven by thin liquidity, news timing, or order-flow imbalances; traders should verify volume, spreads, and whether any specific filing or headline explains the move.

Relevance 4/10Novelty 1/10Timing: premarket before the opening bell

Background

This is a multi-stock premarket movers roundup listing percentage changes for several names before the open.

Company-level read

Ticker impact

$FGIBullishLow confidence
Context

FGI is cited as up 91% in Thursday premarket, signaling a potential momentum move into the regular session.

Expected impact

Higher open risk, with follow-through possible if volume sustains.

Evidence & confidence

The article provides only premarket % change, with no catalyst or news driver, so direction beyond the open is uncertain.

$ARXBullishLow confidence
Context

Accelerant Holdings (ARX) is cited as up 45% in Thursday premarket, indicating a sharp risk-on repricing.

Expected impact

Potential gap-up continuation, but elevated probability of pullback if liquidity fades.

Evidence & confidence

No underlying fundamental or event detail is provided, only the magnitude of the premarket move.

$HLITBullishLow confidence
Context

Harmonic (HLIT) is cited as up 23% in Thursday premarket, marking it as a standout mover for the day.

Expected impact

Choppy upside bias possible at the open, with fast reversals if bids weaken.

Evidence & confidence

The article lacks any specific catalyst, so the move’s persistence is not evidenced.

$CLBTBearishLow confidence
Context

Cellebrite DI (CLBT) is cited as down 28% in Thursday premarket, flagging downside momentum risk.

Expected impact

Higher chance of continued weakness at the open, with potential for oversold bounces.

Evidence & confidence

Only the premarket percentage decline is given; no news or event is described.

$OMERBullishLow confidence
Context

Omeros (OMER) is cited as up 20% in Thursday premarket, placing it among the day’s gainers.

Expected impact

Gap-up continuation possible if early volume persists.

Evidence & confidence

The article provides no fundamental trigger beyond the premarket move.

$LNSRBullishLow confidence
Context

LENSAR (LNSR) is cited as up 18% in Thursday premarket, indicating a sharp early bid.

Expected impact

Potential continuation, but risk of rapid mean reversion is high.

Evidence & confidence

No event detail is included, so persistence is speculative.

$SECZBearishLow confidence
Context

Securitize (SECZ) is cited as down 21% in Thursday premarket, marking it as a notable loser.

Expected impact

Weak open possible, with bounce risk if selling is exhausted.

Evidence & confidence

Only premarket % change is reported; no catalyst is provided.

$CBRSBearishLow confidence
Context

Cerebras Systems (CBRS) is cited as down 17% in Thursday premarket, signaling early downside pressure.

Expected impact

Continuation risk at the open, but oversold snapback possible.

Evidence & confidence

The article lacks any specific news explanation for the move.

Market effects

No sector-level conclusions are supported because the article provides only premarket movers without catalysts.

None specified; the piece is a US premarket snapshot.

None specified; no cross-market or macro linkage is described.

Counterpoint

Without a stated catalyst, the biggest premarket movers (both up and down) can be prone to mean reversion once the open liquidity normalizes.

Key entities

  • FGI Industries Ltd.

    Cited as up 91% in Thursday premarket.

  • Accelerant Holdings

    Cited as up 45% in Thursday premarket.

  • Harmonic Inc.

    Cited as up 23% in Thursday premarket.

  • Cellebrite DI Ltd.

    Cited as down 28% in Thursday premarket.

Related articles

$CBRSMed

Cerebras Drops 20% in a Month: Is the Stock a Buy on the Dip?

Cerebras Systems (CBRS) shares fell 20.4% in a month due to OpenAI partnership concerns, data center delays, and competition. Despite this, demand for AI inference and partnerships with cloud providers like AWS, Oracle, and Microsoft drive growth. CBRS reported Q3 2026 revenue of $230.9M, up 70% YoY, and raised guidance. However, GAAP gross margin contracted to 20% from 40.6% YoY.

$SECZMed

Securitize Acquires River One to Expand Into $6 Trillion Asset-Backed Finance Market

Securitize Corp. (NYSE: SECZ), a digital asset tokenization platform, acquired River One, expanding into the $6 trillion asset-backed finance market. River One specializes in stablecoin-based capital for traditional lending. The deal enhances Securitize's credit origination and asset-backed financing capabilities, with potential revenue from origination fees and financing participation.

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.